<DOC>
	<DOCNO>NCT00000372</DOCNO>
	<brief_summary>The purpose study compare effect D-cycloserine glycine treat negative symptom ( loss interest , loss energy , loss warmth , loss humor ) occur phase positive symptom ( marked hallucination , delusion , think confusion ) schizophrenic . Clozapine currently effective treatment negative symptom schizophrenia . Two drug , D-cycloserine glycine , investigate new treatment . D-cycloserine improves negative symptom add drug , may worsen symptom give clozapine . Glycine also improve negative symptom may still able improve symptom give clozapine . This study give either D-cycloserine glycine ( inactive placebo ) clozapine determine best combination . Patients assign 1 3 group . Group 1 receive D-cycloserine plus clozapine . Group 2 receive glycine plus clozapine . Group 3 receive inactive placebo plus clozapine . Patients receive medication 8 week . Negative symptom schizophrenia monitor Scale Assessment Negative Symptoms , Positive symptom monitor Positive Negative Syndrome Scale , additionally subject complete Brief Psychiatric Rating Scale Global Assessment Scale . An individual may eligible study he/she 18 65 year old diagnose schizophrenia .</brief_summary>
	<brief_title>Glycine D-Cycloserine Schizophrenia</brief_title>
	<detailed_description>To determine glycine produce improvement negative symptom D-cycloserine produce worsen symptom compare placebo , patient undergo double blind study d-cycloserine glycine treatment add clozapine . Clozapine effective negative symptom schizophrenia conventional neuroleptic , neurochemical action contribute superior clinical efficacy remain unclear . Recent evidence point role glutamatergic dysregulation schizophrenia , well important difference conventional agent clozapine effect upon glutamatergic system . D-cycloserine , partial agonist glycine modulatory site N-methyl-D-aspartate ( NMDA ) receptor , improve negative symptom add conventional agent worsen negative symptom add clozapine . High-dose glycine also improve negative symptom provide preliminary evidence suggest glycine improves negative symptom add clozapine . Serum concentration glycine predict response high-dose glycine D-cycloserine . Both clozapine D-cycloserine may improve negative symptom activation glycine modulatory site NMDA receptor complex . Because D-cycloserine partial agonist , may act antagonist glycine site presence clozapine , whereas full agonist , glycine , would expect worsen negative symptom presence clozapine . This study propose administer fixed-dose D-cycloserine , glycine , placebo add clozapine 45 patient schizophrenia . Because assessment standardized study , result study compare result previous study D-cycloserine add conventional neuroleptic . The study ultimately suspend participant enrol , due definitive finding indicate pair treatment D-cycloserine Clozapine result worsen negative symptom .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Diagnosis Schizophrenia Score 27 great Scale Assessment Negative Symptoms ( SANS ) Treatment stable dose clozapine least 4 week Between 18 65 year old No antipsychotic medication oral least 3 month depot form 6 month Current major depressive episode Current substance abuse diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Adult</keyword>
	<keyword>Amino Acids</keyword>
	<keyword>Cycloserine</keyword>
	<keyword>Female</keyword>
	<keyword>Glycine</keyword>
	<keyword>Human</keyword>
	<keyword>Male</keyword>
	<keyword>N-Methylaspartate</keyword>
	<keyword>Placebos</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Amino Acids -- blood</keyword>
	<keyword>Cycloserine -- *therapeutic use</keyword>
	<keyword>Glycine -- *therapeutic use</keyword>
	<keyword>Schizophrenia -- *drug therapy</keyword>
	<keyword>Schizophrenia -- physiopathology</keyword>
</DOC>